Biotechnology/Chemical/Pharmaceutical Customer Partnership

Monday, September 24, 2018
United States Patent and Trademark Office
USPTO Main Campus (Alexandria), Madison Auditorium

10:00 – 10:10am (EDT) Welcoming and Opening Remarks
Gary Jones
Director, TC1600, USPTO
Daniel Sullivan
Director, TC1600, USPTO
Andrew Wang
Director, TC1600, USPTO

10:10 – 11:00am (EDT) Obviousness of Biologics:
Identifying the Biggest Challenges
Carla Mouta-Bellum,
Partner, Arrigo, Lee, Guttman &
Mouta-Bellum LLP

11:00 – 11:50am (EDT) Exemplary Obviousness Rationales
Suggested in KSR
Lora Driscoll
QAS, TC1600, USPTO

11:50am – 12:50pm (EDT) BREAK/LUNCH

12:50 – 1:40pm (EDT) 112(f)-New Form Paragraphs
Marjorie Moran, QAS
TC1600, USPTO

1:40 – 2:40pm (EDT) Requirements for Information
Under 37 CFR 1.105 and
Responses to Said Requirements
Amjad Abraham, SPE
Shubo (Joe) Zhou, SPE
TC1600, USPTO

2:40 – 3:00pm (EDT) BREAK

3:00 – 3:50pm (EDT) Accidental Infringement: the need
for additional limitations in plant
utility claims directed to chemical
profiles or cultivars
Reggie Gaudino,
Chief Science Officer, Steep Hill
Labs, Inc.

3:50 – 4:00pm (EDT) Closing Remarks
Directors, TC1600, USPTO